Document Report Card

Basic Information

ID: ALA1156686

Journal: Eur J Med Chem

Title: Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.

Authors: Reigan P, Gbaj A, Stratford IJ, Bryce RA, Freeman S.

Abstract: Thymidine phosphorylase (TP) is over-expressed in various tumour types and plays an important role in tumour angiogenesis, growth, invasion and metastasis. The enzymatic activity of TP is required for the angiogenic effect of TP, therefore, inhibitors of TP are of significant interest in cancer chemotherapy. A series of xanthine oxidase (XO) activated prodrugs of known inhibitors of TP have been designed and synthesized with the ultimate intent of improving tumour selectivity and pharmacokinetic characteristics. These prodrugs were not inhibitors of TP, but were selectively oxidized by XO at C-2 and/or C-4 of the uracil ring moiety to generate the desired TP inhibitor. Molecular modelling of both the TP inhibitors and XO-activated prodrugs rationalized their binding in the active site of the human TP crystal structure.

CiteXplore: 17870212

DOI: 10.1016/j.ejmech.2007.07.015